Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Spesolimab Efficacy and Safety in Patients with Moderate-to-Severe Palmoplantar Pustulosis: A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase IIb, Dose-Finding Study
A. David Burden, Robert Bissonnette, Alexander A. Navarini, et al.
Dermatology and Therapy (2023) Vol. 13, Iss. 10, pp. 2279-2297
Open Access | Times Cited: 18

Showing 18 citing articles:

Spesolimab for the Treatment of Generalized Pustular Psoriasis
Diana Bernardo, Diamant Thaçi, Tiago Torres
Drugs (2023) Vol. 84, Iss. 1, pp. 45-58
Open Access | Times Cited: 17
Successful treatment of acrodermatitis continua of Hallopeau coexisting with generalized pustular psoriasis with spesolimab: a case report
Pengfei Wen, Chuan Liu, Tingting Wang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 7
The role of the interleukin-36 axis in generalized pustular psoriasis: a review of the mechanism of action of spesolimab
Jason E. Hawkes, Sudha Visvanathan, James G. Krueger
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 11
Off-Label Use of Spesolimab in Dermatology: A Systematic Review
Siddhartha Sood, Jihad Waked, Nabil Merchant, et al.
Journal of Cutaneous Medicine and Surgery (2025)
Closed Access
Intralesional Spesolimab: A Novel and Effective Approach for Palmoplantar Pustulosis Treatment – A Case Report
Sining Wang, Ying-Chun Lu, Yujuan Zhao, et al.
International Medical Case Reports Journal (2025) Vol. Volume 18, pp. 205-209
Open Access
Analysis of Predefined Safety Events Across Spesolimab Trials in Dermatological and Non-Dermatological Conditions
Kenneth B. Gordon, Yayoi Tada, Milan J. Anadkat, et al.
Dermatology and Therapy (2025)
Open Access
Acrodermatitis continua of Hallopeau successfully treated with spesolimab
M. Descos, C. Girard, Maud Girod, et al.
Annales de Dermatologie et de Vénéréologie (2025) Vol. 152, Iss. 2, pp. 103347-103347
Closed Access
Palmoplantar Pustulosis as an Immune-Mediated Inflammatory Disease with a Possible Relevance of Th17 Cell Plasticity: A Narrative Review
Tadashi Terui, Masamoto Murakami, Yukari Okubo, et al.
Dermatology and Therapy (2025)
Open Access
What is “ chronic ” pustular psoriasis? Identifying candidates for long-term subcutaneous spesolimab treatment
Angelo Valerio Marzano, Carlo Alberto Maronese, Anna Balato, et al.
Expert Opinion on Biological Therapy (2025)
Closed Access
Emerging Therapies for Palmoplantar Pustulosis with a Focus on IL-23 Inhibitors
Kyung‐Hwa Nam, Yoon‐Seob Kim
Journal of Clinical Medicine (2025) Vol. 14, Iss. 10, pp. 3273-3273
Open Access
Synovitis, Acne, Pustulosis, Hyperostosis, Osteitis, Palmoplantar Pustulosis, and Neutrophilic Dermatoses: A GRAPPA 2023 Annual Meeting Update
Kristina Callis Duffin, Hok Bing Thio, Philip Helliwell
The Journal of Rheumatology (2024) Vol. 51, Iss. Suppl 2, pp. 77-79
Closed Access | Times Cited: 3
Spesolimab, the first‐in‐class anti‐IL‐36R antibody: From bench to clinic
Akimichi Morita, Yukari Okubo, Shinichi Imafuku, et al.
The Journal of Dermatology (2024) Vol. 51, Iss. 11, pp. 1379-1391
Open Access | Times Cited: 3
Associations of inflammatory cytokines with palmoplantar pustulosis: a bidirectional Mendelian randomization study
Chengling Liu, Xingchen Liu, Haiming Xin, et al.
Frontiers in Medicine (2024) Vol. 11
Open Access | Times Cited: 2
Biologics as a novel treatment option for palmoplantar pustulosis: a comprehensive review
Hio Fong Leong, Wenhui Wang, Fen Peng
Advances in Dermatology and Allergology (2024) Vol. 41, Iss. 3, pp. 262-269
Open Access | Times Cited: 1
Response to: Letter to Editor Regarding “Spesolimab Efficacy and Safety in Patients with Moderate-to-Severe Palmoplantar Pustulosis: A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase IIb, Dose-Finding Study”
A. David Burden
Dermatology and Therapy (2024) Vol. 14, Iss. 4, pp. 1067-1069
Open Access
Letter to the Editor Regarding: Spesolimab Efficacy and Safety in Patients with Moderate-to-Severe Palmoplantar Pustulosis: A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase IIb, Dose-Finding Study
Ruiyao Hu, Yue Wang, Fanzhang Meng, et al.
Dermatology and Therapy (2024) Vol. 14, Iss. 4, pp. 1063-1065
Open Access
Spesolimab: Is it a new treatment target in palmoplantar pustulosis?
Hanjing Huang, Yuru Zhang, Yuanhao Wu, et al.
International Journal of Rheumatic Diseases (2024) Vol. 27, Iss. 5
Open Access
A systematic review of recent randomized controlled trials for palmoplantar pustulosis
Miranda K. Branyiczky, Shahnawaz Towheed, Tiago Torres, et al.
Journal of Dermatological Treatment (2024) Vol. 35, Iss. 1
Open Access
Page 1

Scroll to top